Sunflower Pharmaceutical gets trial approval for pediatric bronchitis drug

Sunflower Pharmaceutical Group Co., Ltd. announced that its wholly-owned subsidiary, Heilongjiang Sunflower Pharmaceutical Co., Ltd., has received a notice of approval from the National Medical Products Administration for the clinical trial of "Xiaor Fere Kaichuan Oral Solution." The approval permits the drug to proceed with clinical trials for its use in children with acute bronchitis. The application was reviewed and concluded on August 4, 2025.

The "Xiaor Fere Kaichuan Oral Solution" is an existing product held by the company. The upcoming clinical trials will build upon the drug's original indications, focusing specifically on its efficacy for "children with acute bronchitis." The company emphasized that this development represents an extension of research into an already marketed product.

Sunflower Pharmaceutical Group cautioned investors that drug review processes are lengthy and involve multiple stages, making the timeline and ultimate approval outcome uncertain. The company pledged to provide timely updates on research progress and urged investors to be aware of the associated investment risks.